HK-001 / Everfront Biotech - LARVOL DELTA

To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=56 | Active, not recruiting | Sponsor: Everfront Biotech Co., Ltd. | Trial completion date: Jun 2025 ➔ Jun 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders

To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=56 | Active, not recruiting | Sponsor: Everfront Biotech Co., Ltd. | Trial completion date: Dec 2023 ➔ Jun 2025 | Trial primary completion date: Jun 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders

To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=56 | Active, not recruiting | Sponsor: Everfront Biotech Co., Ltd. | Trial primary completion date: Dec 2022 ➔ Jun 2023

Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders

To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=56 | Active, not recruiting | Sponsor: Everfront Biotech Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Amyotrophic Lateral Sclerosis • CNS Disorders